Alireza Abidi
Gynecologic Oncology · Sacramento, CANPI 1215919477
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by AstraZeneca at 50.5% of the total. 2025 is the largest year on record at $8,964, more than ten times the $154 reported in 2019.
Across 93 payments — averaging $141.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Intuitive Surgical$3K
- GSK$479
- Caris MPI, Inc.$384
- Stryker$376
- AbbVie$236
- plus $2K from 34 others
What the payments were for
- Consulting fees$6,39849%
- Travel & lodging$5294%
- Food & beverage$3,24425%
- Education$3,00023%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $6,656 |
| Intuitive Surgical | 6 | $3,243 |
| GSK | 9 | $479 |
| Caris MPI, Inc. | 8 | $384 |
| Stryker | 2 | $376 |
| AbbVie | 6 | $236 |
| Genmab U.S., Inc. | 2 | $229 |
| Merck | 5 | $141 |
| Dysis Medical, Inc. | 2 | $138 |
| Pfizer | 1 | $125 |
| Tesaro, Inc. | 1 | $118 |
| Johnson & Johnson | 4 | $107 |
| Eisai Inc. | 3 | $86 |
| Bayer | 2 | $61 |
| Jazz Pharmaceuticals Inc. | 2 | $59 |
| Sobi, Inc | 2 | $51 |
| Incyte Corporation | 2 | $46 |
| Puma Biotechnology, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Beone Medicines USA, Inc. | 1 | $39 |
| AVEO Pharmaceuticals, Inc. | 1 | $35 |
| Genentech USA, Inc. | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Syndax Pharmaceuticals, Inc. | 1 | $29 |
| Array Biopharma Inc | 1 | $29 |
| ADC Therapeutics America, Inc. | 1 | $28 |
| Immunocore Limited | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Adaptive Biotechnologies Corporation | 1 | $27 |
| Novartis | 1 | $27 |
| Servier Pharmaceuticals LLC | 1 | $27 |
| Sanofi | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $22 |
| Iovance Biotherapeutics, Inc. | 1 | $19 |
| Novocure Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Specialty Surgical Instrumentation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$3,000
- ZEJULA$363
- SPY-PHI SYSTEM$340
- MI CANCER SEEK$217
- EPKINLY$200
- Da Vinci Surgical System$182
- TIVDAK$125
- DYSIS Ultra 2.0$124
- DYSIS v3 Digital Coploscope$124
- DYSIS VIEW$124
- LYNPARZA$114
- JEMPERLI$108
How this compares
$13,170 in reported general payments places this provider in the 75th percentile of 152 gynecologic oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 22 | $361,558 |
| LynparzaOlaparib | 18 | $165,581 |
| NivestymFilgrastim-Aafi | 13 | $9,524 |
| Anastrozole | 117 | $3,003 |
| Estradiol | 46 | $2,156 |
| Dexamethasone Sodium Phosphate | 12 | $651 |
| Dexamethasone | 56 | $637 |
| Letrozole | 30 | $574 |
| Gabapentin | 47 | $493 |
| Ondansetron Hcl | 56 | $462 |
| Prednisone | 36 | $444 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $354 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 14 | $316 |
| Clobetasol Propionate | 18 | $279 |
| Prochlorperazine Maleate | 13 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $479 | $361,55822 claims |
| AstraZenecaLynparza | $6,656 | $165,58118 claims |
| PfizerNivestym | $125 | $9,52413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 gynecologic oncology providers in California.
Other gynecologic oncology in Sacramento
- Rebecca BrooksSacramento$133K
- Amanda Shepherd-LittlejohnSacramento$73K
- Melissa PhamSacramento$50K
- Edwin AlvarezSacramento$12K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.